Cargando…
Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine
This study aimed to formulate and evaluate a floating raft system for the co-delivery of etoricoxib (ETO) and famotidine (FAM) using a combination of glucomannan with natural/semi-synthetic polysaccharides. Formulation variables affect gelation lag time (GLT), floating lag time (FLT), and release pe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184610/ https://www.ncbi.nlm.nih.gov/pubmed/36927148 http://dx.doi.org/10.1080/10717544.2023.2189630 |
_version_ | 1785042180127064064 |
---|---|
author | Shoman, Nabil A. Saady, Marwa Teaima, Mahmoud Abdelmonem, Rehab El-Nabarawi, Mohamed A. Elhabal, Sammar Fathy |
author_facet | Shoman, Nabil A. Saady, Marwa Teaima, Mahmoud Abdelmonem, Rehab El-Nabarawi, Mohamed A. Elhabal, Sammar Fathy |
author_sort | Shoman, Nabil A. |
collection | PubMed |
description | This study aimed to formulate and evaluate a floating raft system for the co-delivery of etoricoxib (ETO) and famotidine (FAM) using a combination of glucomannan with natural/semi-synthetic polysaccharides. Formulation variables affect gelation lag time (GLT), floating lag time (FLT), and release percentage of drugs after 1–8 h, Stability, and viscosity parameters were evaluated. In vivo X-ray studies, followed by the pharmacokinetic study, were performed on human volunteers. Formulations exhibited pseudoplastic behavior for ease of swallowing. The optimum raft system (ORS) comprised 1% Na alginate, 0.1% Low Methoxyl (LM) pectin, 0.8% Konjac glucomannan (KGL), 1% Precirol, and 1% CaCO(3). ORS exhibited rapid GLT and FLT (around 42 and 8 sec respectively) in 0.1 N HCl as well as controlled release of ETO (15% in 1 h and 82% in 8 h) and FAM (29% in 1 h and 85% in 8 h). Formulation stability with the absence of any drug-excipient interactions was observed. The X-ray imaging showed a promising buoyancy ability for approximately 8 h. Compared with marketed products, ORS showed superior relative bioavailability for both drugs. These findings revealed the successful preparation of a promising raft system with improved dual drug delivery. |
format | Online Article Text |
id | pubmed-10184610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-101846102023-05-16 Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine Shoman, Nabil A. Saady, Marwa Teaima, Mahmoud Abdelmonem, Rehab El-Nabarawi, Mohamed A. Elhabal, Sammar Fathy Drug Deliv Research Article This study aimed to formulate and evaluate a floating raft system for the co-delivery of etoricoxib (ETO) and famotidine (FAM) using a combination of glucomannan with natural/semi-synthetic polysaccharides. Formulation variables affect gelation lag time (GLT), floating lag time (FLT), and release percentage of drugs after 1–8 h, Stability, and viscosity parameters were evaluated. In vivo X-ray studies, followed by the pharmacokinetic study, were performed on human volunteers. Formulations exhibited pseudoplastic behavior for ease of swallowing. The optimum raft system (ORS) comprised 1% Na alginate, 0.1% Low Methoxyl (LM) pectin, 0.8% Konjac glucomannan (KGL), 1% Precirol, and 1% CaCO(3). ORS exhibited rapid GLT and FLT (around 42 and 8 sec respectively) in 0.1 N HCl as well as controlled release of ETO (15% in 1 h and 82% in 8 h) and FAM (29% in 1 h and 85% in 8 h). Formulation stability with the absence of any drug-excipient interactions was observed. The X-ray imaging showed a promising buoyancy ability for approximately 8 h. Compared with marketed products, ORS showed superior relative bioavailability for both drugs. These findings revealed the successful preparation of a promising raft system with improved dual drug delivery. Taylor & Francis 2023-03-17 /pmc/articles/PMC10184610/ /pubmed/36927148 http://dx.doi.org/10.1080/10717544.2023.2189630 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Research Article Shoman, Nabil A. Saady, Marwa Teaima, Mahmoud Abdelmonem, Rehab El-Nabarawi, Mohamed A. Elhabal, Sammar Fathy Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine |
title | Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine |
title_full | Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine |
title_fullStr | Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine |
title_full_unstemmed | Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine |
title_short | Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine |
title_sort | merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184610/ https://www.ncbi.nlm.nih.gov/pubmed/36927148 http://dx.doi.org/10.1080/10717544.2023.2189630 |
work_keys_str_mv | AT shomannabila mergingkonjacglucomannanwithothercopolymerichydrogelsasacuttingedgeliquidraftsystemfordualdeliveryofetoricoxibandfamotidine AT saadymarwa mergingkonjacglucomannanwithothercopolymerichydrogelsasacuttingedgeliquidraftsystemfordualdeliveryofetoricoxibandfamotidine AT teaimamahmoud mergingkonjacglucomannanwithothercopolymerichydrogelsasacuttingedgeliquidraftsystemfordualdeliveryofetoricoxibandfamotidine AT abdelmonemrehab mergingkonjacglucomannanwithothercopolymerichydrogelsasacuttingedgeliquidraftsystemfordualdeliveryofetoricoxibandfamotidine AT elnabarawimohameda mergingkonjacglucomannanwithothercopolymerichydrogelsasacuttingedgeliquidraftsystemfordualdeliveryofetoricoxibandfamotidine AT elhabalsammarfathy mergingkonjacglucomannanwithothercopolymerichydrogelsasacuttingedgeliquidraftsystemfordualdeliveryofetoricoxibandfamotidine |